ONC1 13B

Drug Profile

ONC1 13B

Alternative Names: ONC 1-13B

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator AllaChem
  • Class Antiandrogens; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer
  • Preclinical Breast cancer

Most Recent Events

  • 19 Feb 2016 Phase-I/II development is ongoing in Russia
  • 01 Nov 2013 Phase-I/II clinical trials in Prostate cancer (hormone-refractory metastatic disease) in Russia (PO)
  • 01 Jan 2013 Preclinical trials in Breast cancer in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top